Genomics and proteomics: Expression arrays in clinical oncology

Annals of Oncology

Volumn 15, Issue SUPPL. 4, 2004, Pages

  Fey, M F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CISPLATIN; FLUOROURACIL; GEMCITABINE; MERCAPTOPURINE; METHOTREXATE; TAXANE DERIVATIVE; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER RESEARCH; COMPUTER PROGRAM; COST; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; FINANCIAL MANAGEMENT; GENE EXPRESSION REGULATION; GENOMICS; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOLECULAR GENETICS; ONCOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; QUALITY CONTROL; RECTUM CANCER; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENOMICS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEOMICS; TREATMENT OUTCOME;

EID: 9744252254     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh921     Document Type: Article

References (18)

1. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
2. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
3. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
4. Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukaemia. Nat Genet 2002; 30: 41-47.
5. Virtanen C, Ishikawa Y, Honjoh D et al. Integrated classification of lung tumours and cell lines by expression profiling. Proc Natl Acad Sci USA 2002; 99: 12357-12362.
6. Heighway J, Knapp T, Boyce L et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002; 21: 7749-7763.
7. Kikuchi T, Daigo Y, Katagiri T et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003; 22: 2192-2205.
8. Buckhaults P, Zhang Z, Chen YC et al. Identifying tumour origin using a gene expression-based classification map. Cancer Res 2003; 63: 4144-4149.
9. Senn HJ, Thürlimann B, Goldhirsch A et al. Comments on the St. Gallen Consensus on the primary therapy of early breast cancer. Breast 2003; 12: 569-582.
10. Van t'Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
11. Perou CM, Serlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
12. Cheok MH, Yang W, Pui CH et al. Treatment-specific changes in gene-expression discriminate in vivo drug response in human leukaemia cells. Nat Genet 2003; 34: 85-90.
13. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to anti-androgen therapy. Nat Med 2004; 10: 33-39.
14. Clarke PA, George ML, Easdale S et al. Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res 2003; 63: 6855-6863.
15. Ramaswamy S, Tamayo P, Rifkin R et al. Multiclass cancer diagnosis using tumour gene expression signatures. Proc Natl Acad Sci USA 2001; 98: 15149-15154.
16. Fey MF. Impact of the Human Genome Project on the clinical management of sporadic cancers. Lancet Oncol 2002; 3: 349-356.
17. Aitman TI. DNA microarrays in medical practice. BMJ 2001; 323: 611-615.
18. Mohr S, Leikauf G, Keith G, Rihn BH. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 2002; 20: 3165-3175.